Journal: JACC: Basic to Translational Science

Article Title: PCSK9 Modulates the Secretion But Not the Cellular Uptake of Lipoprotein(a) Ex Vivo

doi: 10.1016/j.jacbts.2016.06.006

Figure Lengend Snippet: PCSK9 Treatment Increases Apo(a) Secretion From Primary Human Hepatocytes: An Effect Blocked by Alirocumab Cells were treated with increasing concentrations of recombinant PCSK9 with or without alirocumab for 72 h. ApoB100 (A) and apo(a) (B) were quantified in the culture medium by enzyme-linked immunosorbent assay and liquid chromatography-tandem mass spectrometry, respectively. *p < 0.05 vs. control (no PCSK9). **p < 0.05 vs. same dose of PCSK9 without alirocumab, using 1-way analysis of variance on rank-transformed values with post-hoc Newman-Keuls test. Histograms represent the mean ± SEM of 3 independent experiments from 2 hepatocyte donors. Abbreviations as in Figure 1 .

Article Snippet: Lp(a), either reduced with 50 mmol/l dithiothreitol or not reduced, was subjected to sodium dodecyl sulfate polyacrylamide gel electrophoresis on 4% to 12% Tris-Glycine gels (Thermo Fisher Scientific); transferred onto nitrocellulose membrane; and immunoblotted with a rabbit monoclonal anti-human apo(a) antibody, clone EPR6474, and an antirabbit immunoglobulin G horseradish peroxidase secondary antibody (OriGene, Rockville, Maryland).

Techniques: Recombinant, Enzyme-linked Immunosorbent Assay, Liquid Chromatography, Mass Spectrometry, Transformation Assay